Диссертация (1139742), страница 20
Текст из файла (страница 20)
— С. 86–87.71.ХарченкоП.В.Диагностикалокализованногоракапредстательной железы: Автореф. дисс. ... канд. мед. наук. — СПб., 2003. —20 с.72.методики,Харченко В.П., Котляров П.М. Рак предстательной железы —семиотика,задачиипроблемылучевойМедицинская визуализация.
— 2002. — №3. — С. 4–10.диагностики//15573.Харченко В.П., Рожкова Н.И., Котляров П.М. Современныетенденции и прогноз развития лучевой диагностики // Вестник рентгенологиии радиологии. — 2006. — №6. — С. 36–38.74.ЧиссовВ.И.,ДарьяловаС.Л.Онкология:Пособиедляонкологов. — М.: ГЭОТАР-Медиа, 2006. — 700 с.75.Чиссов В.И., Дарьялова С.Л. Клинические рекомендации.Онкология. — 2-е изд., испр. и доп. — М.: ГЭОТАР-Медиа, 2009.
—С. 540–578.76.Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественныеновообразования в России в 2011 году (заболеваемость и смертность). — М.:ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2013. — 289 с.77.Шария М.А. Магнитно-резонансная томография в диагностикеновообразований почек, мочевыводящих путей и предстательной железы.Дисс. … докт. мед.
наук. — 2009. — 267 с.78.Abdel-Khalek M., El-Baz M., Ibrahiem H. Predictors of prostatecancer on extended biopsy in patiens with high-grade prostatic intraepithelialneoplasia: a multivariate analysis model // BJU Int. — 2004. — Vol. 94. —№4. — P. 528–533.79.Adusumilli S., Pretorius E.S. Magnetic resonance imaging of prostatecancer // Urol.
Oncol. — 2002. — Vol. 20, №3. — P. 192–210.80.Akin O., Sala E., Moskowitz C.S. et al. Transition zone prostatecancers: features, detection, localization, and staging at endorectal MR imaging //Radiology. — 2006. — Vol. 239. — №3. — P.784–792.81.Akin O., Hricak H. Imaging of prostate cancer // Radiol. Clin.
N.Am. — 2007. — Vol. 45. — P. 207–222.82.Amiel G.E., Slawin K.M. Newer modalities of ultrasound imaging andtreatment of the prostate // Urol. Clin. N. Am. — 2006. — Vol.33. — №3. —P. 329–337.15683.Amsellem-Ouazana D., Younes P, Conquy S. et al. Negative prostaticbiopsies in patients with a high risk of prostate cancer. Is the combination ofendorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a usefultool? A preliminary study // Eur. Urol.
— 2005. — Vol. 47. — №5. —P. 582–586.84.Barbieri A., Incarbone P., Giacomo B. et al. Valori е limitidellecografia transrettale е della tomografia computerizzata nella stadiazionepreoperatoria del carcinoma prostatico // Acta Biomed. Ateneo Parmense. —1997. — Vol. 68. —№1/2. — P.
23–26.85.Barentsz J.O. et al. ESUR prostate MR guidelines 2012// Eur. Radiol.2012. — Vol. 22. — №4. — Р. 746–757.86.Blake M.A., Kalra M.K. Imaging of urinary tract tumors / Imaging inOnkology. — Springer, 2008. — P. 299–317.87.Bloch B.N., Furman-Haran E., Helbich T.H. et al. Prostate cancer:accurate determination of extracapsular extension with high-spatial resolutiondynamic contrast-enhanced and T2-weihted MR imaging-initial results //Radiolody. — 2007.
— Vol. — 245. — №1. — P.176–185.88.Charles-Edwards E.M., Desouza N.M. Diffusion-weighted magneticresonance imaging and its application to cancer // Cancer Imaging. — 2006. —Vol. 16. — Р. 135–143.89.Chen M., Dang H.D., Wang J.Y. et al.Prostate cancer detection:comparison of T2-weighted imaging, proton magnetic resonance spectroscopicimaging, and the three techniques combined // Acta Radiol. — 2008. —Vol. 49. — №5.
— P. 602–610.90.Cheikh A.B., Girouin N., Colombel M. et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer beforerepeat biopsy // Eur. Radiol. — 2009. — Vol.19. — №3. — P.770–778.91.Choi Y.J., Kim J.K., Kim N. et. al.
Functional MR imaging of prostatecancer // Radiographics . — 2007. — Vol. 27. — №1. — P. 63–75.15792.Choyke P.L. Imaging of prostate cancer // Abdom. Imaging. —1995. — Vol. 20. — №6. — P. 505–515.93.Cirillo S., Petracchini M., Della Monica P. et al. Value of endorectalMRI and MRS in patients with elevated prostate-specific antigen levels andprevious negative biopsies to localize peripheral zone tumours // Clin. Radiol. —2008.
— Vol. 63. — №8. — Р. 871–879.94.Coakley F.V., Kurhanewicz J., Lu Y. et al. Prostate cancer tumorvolume: measurement with endorectal MR and MR spectroscopic imaging //Radiology. — 2002. — Vol. 223. — P. 91–97.95.monitoredCohen J.S. Phospholipid and energy metabolism of cancer cellsby31Pmagneticresonancespectroscopy:possibleclinicalsignificance // Mayo Clin. Proc.1988. — Vol. 63. — P. 1199–1207.96.Costello L.C., Littleton G.K., Franklin R.B.
Regulation of citrate-related metabolism in normal and neoplastic prostate / Endocrine control inneoplasia. —New York, NY: Raven, 1978. — P. 303–314.97.Costello L.C., Franklin R.B. Novel role of zinc in the regulation ofprostate citrate metabolism and its implications in prostate cancer // Prostate. —1998. — Vol. 35. — №4. — P. 285–296.98.Costello L.C., Franklin R.B.
The intermediary metabolism of theprostate: a key to under¬standing the pathogenesis and progression of prostatemalignancy // Oncology. — 2000. — Vol. 59. — №4. — P. 269–282.99.Costouros N.G., Coakley F.V., Westphalen A.C. et al. Diagnosis ofprostate cancer in patients with an prostate-specific antigen level: role ofendorectal MRI and MR spectroscopic imaging // AJR. — 2007. — Vol. 188. —Р.
812–816.100. Daly P.F., Lyon R.C., Faustino P.J. et al. Phospholipid metabolism incancer cells monitored by 31P NMR spectroscopy // J. Biol. Chem. — 1987. —Vol. 262. — №31. — P. 14875–14878.158101. De Souza N.M., Riches S.F., Vanas N.J. et al. Diffuzion-weightedmagnetic resonance imaging: a potential non-invasive marker of tumoraggressiveness in localized prostate cancer // Clin.
Radiol. — 2008. — Vol. 63. —№7. — P. 774–782.102. De Souza N. M., Reinsberg S.A., Scurr E.D., Brewster J.M., PayneG.S. Magnetic resonance imaing in prostate cancer the value of apparent diffusioncoefficients for identifying malignant nodules // Br. J. Radiol. — 2007. — Vol.80. — №850. — P. 90–95.103. Dewhirst M.W., Sostman H.D., Leopold K.A. et al. Soft-tissuesarcomas: MR imaging and MR spectroscopy for prognosis and therapymonitoring-work in progress // Radiology. — 1990. — Vol. 174. — P. 847–853.104. Djavan B., Ravery A., Zlotta V. et al. Prospective evaluation ofprostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? // J.Urol. — 2001.
— Vol. 166. — P. 1679–1683.105. Djavan B., Remzi M., Marberger M. When to biopsy and when to stopbiopsying // Urol. Clin. North. Am. — 2003. — Vol. 30. — №2. —P. 253–262.106. Dotan Z.A. Bone imaging in prostate cancer // Nat. Clin. Pract.Urol. — 2008. — Vol. 5. — №8. — P.
1228–1242.107. Engelhard K., Hollenbach H.P., Deimling M. et al. Combination ofsignal intensity measurements of lesions in the peripheral zone of prostate withMRI and serum PSA level for differentiating benign disease from prostate cancer //Eur. Radiol. — 2000. — Vol. 10. — №12. — P. 1947–1953.108. Epstein J.I., Allsbrook W.C.Jr., Amin M.B., Egevad L.L. The 2005Internatonal society of urological pathology (ISUP) consensus conference onGleason grading of prostatic carcinoma // Am. J. Surg. Pathol.
— 2005. —Vol. 29. — №9. — P. 1228–1242.159109. Fielding, J.R. Pelvis / Computed body tomography with MRIcorrelation, ed. by J.K.T. Lee, S.S. Sagel, R.J. Stanley, J.P. Heiken. — 4th ed. —Philadelphia: Lippincott Williams&Wilkins, 2006. — P. 1375–1415.110. Feliciano J., Teper E., Ferrandino M. et al. The incidence offluoroquinolone resistant infections after prostate biopsy — are fluoroquinolonesstill effective prophylaxis // J. Urol. — 2008. — Vol. 179. — №3. — Р. 952–955.111. Ferlay J., Parkin D.M., Sterliarova-Foucher E.
Estimates of cancerincidence and mortality in Europe in 2008 // Eur. J. Cancer. — 2010. —Vol. 46. — №4. — P. 765–781.112. Franiel T., Ludemann L., Rudolph B. et al. // Evaluation of normalprostate tissue, chronic prostatitis, and prostate cancer by quantitave perfusionanalysis using a dynamic contrast-enhanced inversion-prepared dual-contrastgradient echo sequence // Radiol. — 2008.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
